Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qingqing Ding

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
Molecular Cell|October 13, 2009
KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbetaDung-Fang Lee, Hsu-Ping Kuo, Mo Liu, et al.
Cancer Research|August 5, 2008
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancerQingqing Ding, Longfei Huo, Jer-Yen Yang, et al.
Cancers|January 11, 2024
Intragenic <i>EGFR::EGFR</i>.E1E8 Fusion (EGFRvIII) in 4331 Solid TumorsLan Zheng, Rajyalakshmi Luthra, Hector A Alvarez, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 4, 2020
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancerDi Ai, Jun Yao, Fei Yang, et al.
Cancer Cell|November 22, 2016
Deubiquitination and Stabilization of PD-L1 by CSN5Seung-Oe Lim, Chia-Wei Li, Weiya Xia, et al.
Cell|August 19, 2007
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathwayDung-Fang Lee, Hsu-Ping Kuo, Chun-Te Chen, et al.
Human Pathology|April 25, 2018
Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancerQingqing Ding, Yan Wang, Zhuang Zuo, et al.
Nature Communications|August 31, 2016
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activityChia-Wei Li, Seung-Oe Lim, Weiya Xia, et al.
Human Pathology|January 22, 2022
Expression of TRPS1 in phyllodes tumor and sarcoma of the breastJing Wang, Wei-Lien Wang, Hongxia Sun, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
Molecular Cell|October 13, 2009
KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbetaDung-Fang Lee, Hsu-Ping Kuo, Mo Liu, et al.
Cancer Research|August 5, 2008
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancerQingqing Ding, Longfei Huo, Jer-Yen Yang, et al.
Cancers|January 11, 2024
Intragenic <i>EGFR::EGFR</i>.E1E8 Fusion (EGFRvIII) in 4331 Solid TumorsLan Zheng, Rajyalakshmi Luthra, Hector A Alvarez, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 4, 2020
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancerDi Ai, Jun Yao, Fei Yang, et al.
Cancer Cell|November 22, 2016
Deubiquitination and Stabilization of PD-L1 by CSN5Seung-Oe Lim, Chia-Wei Li, Weiya Xia, et al.
Cell|August 19, 2007
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathwayDung-Fang Lee, Hsu-Ping Kuo, Chun-Te Chen, et al.
Human Pathology|April 25, 2018
Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancerQingqing Ding, Yan Wang, Zhuang Zuo, et al.
Nature Communications|August 31, 2016
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activityChia-Wei Li, Seung-Oe Lim, Weiya Xia, et al.
Human Pathology|January 22, 2022
Expression of TRPS1 in phyllodes tumor and sarcoma of the breastJing Wang, Wei-Lien Wang, Hongxia Sun, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
Pageof 14